Urine Drug Testing (UDT) in Pain Management. Nov 27, 2017

Size: px
Start display at page:

Download "Urine Drug Testing (UDT) in Pain Management. Nov 27, 2017"

Transcription

1 Urine Drug Testing (UDT) in Pain Management Nov 27, 2017

2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.

3 Learning Objectives How and when to use urine drug testing (UDT) as part of a comprehensive management plan when prescribing opioids for chronic non-cancer pain Discuss how to manage unexpected UDT results

4 Urine Drug Testing (UDT) Management tool for patients treated with controlled substances or at risk for substance use May use UDT as an option for assessment and should be aware of benefits and limitations, appropriate test ordering and interpretation, and have a plan to use results

5 Prior to UDT Inform the patient Take careful history of medication/drug use in the past week Collect the sample in physicians office; ensure proper labelling

6 Point of Care Testing Rapid test performed in clinic e.g. urine dipsticks, cups Immunoassay drug screens are designed to classify substances as either present or absent according to a predetermined cut-off threshold When the amount of drug in the urine sample is equal to or exceeds the cut off concentration of a particular device, the outcome is a positive result POINT OF CARE (POC) LABORATORY TESTING COMPARISON

7 Laboratory Testing Specimen sent to laboratory Gas or Liquid Chromatography/ Mass Spectrometry is a more definitive laboratory based procedure to identify specific drug and/or metabolites and is needed in 3 instances: To specifically identify the drug; for example, that morphine is the opiate causing the positive immunoassay response To identify drugs not otherwise included in other testing To contest results disputed by the patient POINT OF CARE (POC) LABORATORY TESTING COMPARISON

8 Comparison - ADVANTAGES Point of Care -Immunoassay Rapid Results Concurrently test for multiple drug classes Very responsive for morphine and codeine Laboratory - Chromatography Identifies specific drug Confirmation of results More accurate for semisynthetic and synthetic opioids Does not cross react with poppy seeds POINT OF CARE (POC) LABORATORY TESTING COMPARISON

9 Validation Patients may tamper with urine samples to hide aberrant behaviours by: adding adulterants diluting the sample substituting another individuals sample for their own ingesting excessive water or diuretics prior to giving a sample Tests performed to improve the reliability of urine sample results NORMAL CHARACTERISTICS OF A URINE SPECIMEN Temperature (within 4 mins) Degrees Celcius ph Urinary Creatinine >20 mg/dl Specific Gravity >1.003

10 What To Do With Abnormal UDT Results: General Approach Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory (potential for false positive and false negative) Check with lab re: potential error What kind of urine test was done? Interpret results in the context of the patient s clinical presentation and assessments Possibly ask the lab to re-run the sample with chromotgraphy if response still unclear UDT, urine drug test.

11 Unexpected Results Case Table of Contents Is the patient taking the opioid I prescribed? I didn t prescribe that! I didn t expect to find that in your urine sample!

12 Unexpected Results Case 1 Is the patient taking the opioid I prescribed?

13 John 39 year old male Currently taking CR oxycodone resistant to crushing 40 mg q12h for chronic back pain On duloxetine 60 mg daily for some neuropathic features with effect Using some quetiapine 25 qhs to sleep ORT score: 8 1 for age 4 for use of THC in college, enough that he failed a semester, then righted himself and graduated, now denies using any 3 for Dad having an alcohol problem; folks split up when he was young due to it.

14 14

15 You do a routine urine on visit today Shows THC Negative for oxycodone, TCAs, benzodiazepines Now what do you do?

16 Would you? A) Fire him as he is lying to you? B) Tell him that you can no longer prescribe opioids as he is not taking them anyways? C) Confront him about the THC? D) Check when he last took CR oxycodone resistant to crushing? E) Call the lab to check the results? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory

17 Available at: Interpreting Unexpected Results of Urine Drug Screens Unexpected Result UDS negative for prescribed opioid Possible Explanations False negative Non-compliance Diversion Actions for the Physician Table B-3.1 Repeat test using chromatography; specify the drug of interest (e.g. oxycodone often missed by immunoassay) Take a detailed history of the patient s medication use for the preceding 7 days (e.g. could learn that patient ran out several days prior to test) Ask patient if they ve given the drug to others Monitor compliance with pill counts

18 John Restarted marijuana use and problems at work and home Financial issue selling CR oxycodone and some quetiapine CR oxycodone discontinued (should this be tapered?) Quetiapine prescribing decreased to 7days supply Offered resources for drug counselling and treatment programs Revised ORT score - High Risk Regular and random UDT

19 Unexpected Results Case 2 I didn t prescribe that!

20 Mary 66 year old female Spinal stenosis 2 failed surgeries in 1999 and 2006 Intolerant of NSAIDS/ COX-2 No personal of family history of drugs or alcohol No history of mental health issues

21 Mary Has taken acetaminophen 650 QID on a regular basis Reports constipation with acetaminophen/codeine 30mg (not filled Rx in 1 year) Reports significantly decreased QoL over last 6 months After exhausting more physical and psychological modalities, you are considering a trial of oxycodone 5mg

22 Mary Baseline UDT recommendation roadmap Do this on everyone UDS immunoassay is positive for benzodiazepines and opioids

23 Mary Now what do you do? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory

24 Available at: Interpreting Unexpected Results of Urine Drug Screens Table B-3.1 Unexpected Result Possible Explanations Actions for the Physician UDS positive for nonprescribed opioid or benzodiazepines False positive. Patient acquired opioids from other sources (doubledoctoring, street ) Repeat UDS regularly Ask the patient if they accessed opioids from other sources Assess for opioid misuse/addiction (See Guideline, Part B, Recommendation 12) Review/revise treatment agreement

25 Known Agents To Cause Interference in Urine Drug Test Results Opioids Marijuana Cocaine Amphetamines Benzodiazepines Dextromethorphan Diphenhydramine (methadone assay only) Poppy seeds Quinine Quinolone antibiotics Rifampin Verapamil (methadone assay only) Efavirenz Hemp seed NSAIDs PPIs Tolmetin Coca leaf tea Amantadine Bupropion Chlorpromazine Desipramine Labetalol Methylphenidate Phentermine Phenylephrine Pseudoephedrine Ranitidine Selegiline Tolmetin Trazodone Typical antipsychotics Oxaprozin Sertraline NSAID, non-steroidal anti-inflammatory drug. PPI, proton pump inhibitor. Adapted from Peppin JF, et al. Pain Med 2012;13: , Reisfield et al Ann Clin Lab Med 1997, Piergies et al Arch Path Lab Med 1997

26 Mary Explanation of Mary's results: Benzodiazepines: Occasionally takes her sisters diazepam 5mg pills Uses acetaminophen/codeine 8mg on a regular basis (up to 8 per day)

27 Mary Explanation of Mary's results: Benzodiazepines: Diazepam metabolizes to nordiazepam, temazepam and oxazepam. Opioids Codeine metabolizes to morphine

28 Benzodiazepines and Opioids Increases the risk of sedation, overdose, and diminished function in all patients, especially as age advances Benzodiazepines increase opioid toxicity and risk of overdose Canadian Guideline for Safe and Effective Use of Opioids for CNCP Part B

29 Mary The presence of a substance that we are not expecting to find can be used to educate patients on safety of drug interactions and toxicity Mary was counseled on the danger of acetaminophen toxicity and use of benzodiazepines Additional counseling points: Definition of misuse Information on safe storage, no sharing, safe disposal, etc. Opioid Treatment Agreement

30 Mary Treatment Plan Not start oxycodone prescriptions for now Explore reasons for benzodiazepine use and possible nonbenzodiazepine treatments for this (medication, psychological, behavioural) Repeat urine test in 3-4 weeks to ensure benzodiazepines are now negative (diazepam can remain positive for 3 weeks) Ensure Mary's daily acetaminophen intake is below a level of concern

31 Unexpected Results Case 3 I didn t expect to find that in your urine sample!

32 Frank 34 year old male C6-7 fracture from snowmobile accident subsequent fusion C5 to T1 PMHx ADD SHx Recently separated with 2 children Smoker 1 ppd ETOH max 3 per day and 15 per week Denies street drug use FHx mental illness - ADD

33 Frank Meds Oxycodone-acetaminophen 1-2 Q4h PRN 8 per day Meloxicam 15mg PO Qdaily Tx No change with physio, chiro, acupuncture VAS Neck pain 8/10 radiating to trapezius and shoulder bilaterally

34 Frank CAGE-AID Low Risk Opioid Risk Tool 4/7 moderate risk Male age Hx of ADD 2 Current depression 1

35 Assessment UDS immunoassay in office Opiates EDDP Oxycodone Cocaine TCA - negative negative positive positive negative Now what do you do? Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory

36 Available at: Interpreting Unexpected Results of Urine Drug Screens Table B-3.1 Unexpected Result Possible Explanations Actions for the Physician UDS positive for illicit drugs (e.g. cocaine, cannabis) False positive Patient is occasional user or addicted to the illicit drug Cannabis is positive for patients THC:CBD (Sativex ) or using medical marijuana Repeat UDS regularly Assess for abuse/addiction and refer for addiction treatment as appropriate Ask about medical prescription of THC:CBD or medical marijuana access program

37 Known Agents To Cause Interference in Urine Drug Test Results Opioids Marijuana Cocaine Amphetamines Benzodiazepines Dextromethorphan Diphenhydramine (methadone assay only) Poppy seeds Quinine Quinolone antibiotics Rifampin Verapamil (methadone assay only) Efavirenz Hemp seed NSAIDs PPIs Tolmetin Coca leaf tea Amantadine Bupropion Chlorpromazine Desipramine Labetalol Methylphenidate Phentermine Phenylephrine Pseudoephedrine Ranitidine Selegiline Tolmetin Trazodone Typical antipsychotics Oxaprozin Sertraline NSAID, non-steroidal anti-inflammatory drug. PPI, proton pump inhibitor. Adapted from Peppin JF, et al. Pain Med 2012;13: , Reisfield et al Ann Clin Lab Med 1997, Piergies et al Arch Path Lab Med 1997

38 Frank Admitted to cocaine use intermittently Offered resources for drug counselling and treatment programs Revised ORT score - High Risk Regular and random UDT Treated with non opioid pharmaceuticals and modalities; or Structured opioid treatment with tight boundaries

39 Random UDTs When a patient steps out of bounds Explain need for good communication system patient cell # or answering system After seeing pt, choose some random dates and record on chart Receptionist writes down in a daily TO-DO list and calls pt by 10:00am to come in Patient has 24hrs to comply or violation

40 What if? He does not admit to the use? Denies it vehemently? Gets angry and defensive? What are your next options?

41 Summary UDS is a recommendation in The Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain UDS point of care immunoassay and laboratory chromatography have different advantages/disadvantages and limitations Your first action with an unexpected result should be Take careful history of medication/drug use in the past week and discuss openly with the patient without being accusatory Each type of unexpected result has a DDx and appropriate physician actions

Urine Drug Testing (UDT) to Monitor Opioid Use. Feb 2018

Urine Drug Testing (UDT) to Monitor Opioid Use. Feb 2018 Urine Drug Testing (UDT) to Monitor Opioid Use Feb 2018 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Urine Drug Testing (UDT) in Pain Management. Nov 5, 2017

Urine Drug Testing (UDT) in Pain Management. Nov 5, 2017 Urine Drug Testing (UDT) in Pain Management Nov 5, 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Prescribing Opioid for. Opioid Naïve Patients AN OPIOD RX

Prescribing Opioid for. Opioid Naïve Patients AN OPIOD RX Prescribing Opioid for Opioid Naïve Patients AN OPIOD RX Optimal Approach to Initiating Opioids for Chronic Non-Cancer Pain AN OPIOID RX Assessment biopsychosocial Non-opioid treatments Opioid risks vs.

More information

Urine Drug Testing Methods 3-5

Urine Drug Testing Methods 3-5 Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry

More information

The Utility of Urine Drug Screening

The Utility of Urine Drug Screening The Utility of Urine Drug Screening Treating Addiction, Saving Lives Sea Cruises Bye Tazmania, still far from New Zealand February 8 th, 2018 Mandy Manak, MD FASAM, ISAM, CSAM, MRO Medical Director, ICDO

More information

3/8/2018. Reasons for Doing UDT. UDT: A Tool in Risk Assessment. Faculty/Presenter Disclosure. Urine Drug Testing in Chronic Pain Management

3/8/2018. Reasons for Doing UDT. UDT: A Tool in Risk Assessment. Faculty/Presenter Disclosure. Urine Drug Testing in Chronic Pain Management Urine Drug Testing in Chronic Pain Management March 8, 2018 Faculty/Presenter Disclosure Faculty: Andrew J Smith, MDCM Relationships with commercial interests: None to report Andrew J Smith, MDCM Staff

More information

Urine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017

Urine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017 Urine Drug Screening (UDS) Dr. Erica L. Weinberg December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any

More information

10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?

10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent? Objectives Drug Testing Interpretation in Addiction Care Brandi Puet, Pharm.D. Describe the difference between immunoassay and confirmatory testing. List explanations for unexpected negative or positive

More information

Controlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing

Controlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing Controlled Substances Evidence-based Tips for Improved Workflow: Diagnosis, Screening & Drug Testing Mississippi Primary Health Care Association Pearl, MS March 7, 2018 Scott Hambleton, MD, DFASAM Medical

More information

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016 Urine Drug Testing Methadone/Buprenorphine 101 Workshop Ron Joe, MD, DABAM December 10, 2016 Learning objectives Clarify the purpose of urine drug testing (UDT) Distinguish between UDT for detection of

More information

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Controlled Substance Monitoring in the Age of the Opioid Epidemic Controlled Substance Monitoring in the Age of the Opioid Epidemic Paul E. Hilliard, MS, MD Hospital Pain Committee Chair Department of Anesthesiology CME housekeeping I have no financial disclosures AKA,

More information

Testing for Controlled Substances

Testing for Controlled Substances Testing for illicit drugs Testing for Controlled Substances 1 Purposes: Employment Sports Screening medical eval. Legal Monitoring Treatment Probation Prescribing controlled substances Forensics 2 Drug

More information

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Dr. Bhushan M. Kapur Associate Professor Department of Laboratory Medicine and Pathobiology, Faculty

More information

Overview. Opioids and HIV Infection: From Pain Management to Addiction Treatment

Overview. Opioids and HIV Infection: From Pain Management to Addiction Treatment FORMATTED: 01/23/2017 New York, New York: February 24, 2017 Opioids and HIV Infection: From Pain Management to Addiction Treatment Chinazo Cunningham, MD, MS Professor of Medicine Albert Einstein College

More information

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient Approaches to Responsible Opioid Prescribing The Opioid Naïve Patient Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain Faculty Disclosure Henry C. Nipper, PhD, DABCC Dr. Nipper has listed no financial interest/arrangement that would be considered a conflict of interest. Urine Drug Testing to Monitor Opioid Use In Managing

More information

URINE DRUG TOXICOLOGY

URINE DRUG TOXICOLOGY Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences URINE DRUG TOXICOLOGY Suzanne E. Rapp, MD GENERAL DISCLOSURES The University of Washington School of Medicine also

More information

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Physician s Reference for Urine and Blood Drug Testing and Interpretation Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine

More information

PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN

PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN 1 OPIOID USE DISORDER IN WOMEN Recognition & Prevention Date: August 14 th, Time: 8 am Presenters: Deepa Nagar MD, Andria Peterson PharmD Maternal Treatment

More information

Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, PM

Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, PM Caring for ME Webinar: Urine Drug Screening Speaker: Dr. Jonathan Fellers Tuesday, November 20, 2018 12 1 PM Audio is available through your computer speakers. Mission Maine Quality Counts is a nonprofit

More information

Patient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM

Patient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM Patient-Centered Urine Drug Testing Douglas Gourlay, MD, MSc, FRCPC, FASAM Declaration of Potential Conflict of Interest The content of this presentation is non- commercial and does not represent any conflict

More information

Learning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly

Learning Objectives. Drug Testing 10/17/2012. Utilization of the urine drug screen: The good, the bad, and the ugly Utilization of the urine drug screen: The good, the bad, and the ugly Jennifer A. Lowry, MD Chief, Section of Medical Toxicology Children s Mercy Hospital Kansas City, MO Learning Objectives Describe the

More information

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW) Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer

More information

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017

Welcome! Supreme Court of Ohio Specialized Dockets Conference. October 23-24, 2017 Welcome! Supreme Court of Ohio Specialized Dockets Conference October 23-24, 2017 Drug Testing: Do you know enough to be dangerous? Presented by William L. Parker President & CEO American Court & Drug

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Drug Testing in Pain Management and Substance Abuse Treatment File Name: Origination: Last CAP Review: Next CAP Review: Last Review: drug_testing_in_pain_management_and_substance_abuse_treatment

More information

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch

More information

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies.   9/20/17 You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies Jeffrey Fudin, BS, PharmD, FCCP, FASHP www.paindr.com Disclosures Astra Zeneca (Speakers Bureau) Collegium (Consultant) Daiichi

More information

Drug Testing in Pain Management and Substance Use Disorder Treatment

Drug Testing in Pain Management and Substance Use Disorder Treatment Drug Testing in Pain Management and Substance Use Disorder Treatment Policy Number: 2.04.98 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City

More information

Goals decided with patient: Mild-to-Moderate Pain First- line: codeine or tramadol Second-line: morphine, oxycodone or hydromorphone

Goals decided with patient: Mild-to-Moderate Pain First- line: codeine or tramadol Second-line: morphine, oxycodone or hydromorphone The Opioid Manager is designed to be used as a point of care tool for providers prescribing opioids for chronic non cancer pain. It condenses key elements from the ACanadian Opioid Guideline and can be

More information

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with

More information

Urine drug testing it s not always crystal clear

Urine drug testing it s not always crystal clear Urine drug testing it s not always crystal clear Kirk Moberg, MD, PhD, FASAM Executive Medical Director, UnityPoint Health Illinois Institute for Addiction Recovery Clinical Professor of Internal Medicine

More information

Gold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine?

Gold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine? Gold Standard for Urine Drug Testing Developed by TRMC Pain Management Center Jill Duffy, RN,BC Pam Kennell, RN, BC Heidi Beisch, RN Urine Drug Testing A DIAGNOSTIC tool For an OBJECTIVE test Based on

More information

Organizing your Practice for Efficient Pain Assessment. Session #4 Roman D. Jovey, MD

Organizing your Practice for Efficient Pain Assessment. Session #4 Roman D. Jovey, MD Organizing your Practice for Efficient Pain Assessment Session #4 Roman D. Jovey, MD 2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Chronic Opioid Therapy Safe Prescribing in Primary Care. Part 3

Chronic Opioid Therapy Safe Prescribing in Primary Care. Part 3 Chronic Opioid Therapy Safe Prescribing in Primary Care Part 3 Michael Mangione, MD Chief of Anesthesia and Director of Pain Service VA Pittsburgh Health Care System Nancy Wiedemer,CRNP VISN 4 Pain Management

More information

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG

More information

How Can a Methadone and an Opiate-Positive Immunoassay Result be Reconciled in a Patient Prescribed only OxyContin and Wellbutrin?

How Can a Methadone and an Opiate-Positive Immunoassay Result be Reconciled in a Patient Prescribed only OxyContin and Wellbutrin? 190 Available online at www.annclinlabsci.org How Can a Methadone and an Opiate-Positive Immunoassay Result be Reconciled in a Patient Prescribed only OxyContin and Wellbutrin? Jude M. Abadie Department

More information

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) 1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces

More information

Clinical contracts. Dr. Johan Wouterloot Prescribers Course April 28, 2017

Clinical contracts. Dr. Johan Wouterloot Prescribers Course April 28, 2017 Clinical contracts Dr. Johan Wouterloot Prescribers Course April 28, 2017 Why? Ameliorates power imbalance States a goal for the agreed upon activity Allows for contingency management to keep behaviour

More information

Conflict of Interest Disclosure

Conflict of Interest Disclosure Patient Rx Drug Misuse and Abuse: Compliance Toxicology Monitoring in Clinical Practice Toxicology Staff Andrea Terrell, Ph.D., DABCC Chief Scientific Officer George Behonick, Ph.D., DABFT, Manager, FBU

More information

Drug Screening. Separating Facts from Myths

Drug Screening. Separating Facts from Myths Drug Screening Separating Facts from Myths Today s Presenter: Todd Shoulberg, EVP ClearStar Medical Information Services Todd Shoulberg, Executive Vice President of Medical Information Services for ClearStar,

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

Cutoff levels for hydrocodone in a blood test

Cutoff levels for hydrocodone in a blood test Cutoff levels for hydrocodone in a blood test The premier DNA and drug testing company in the North Texas area. Specializing in legal cases but also provide testing for employers and private individuals.

More information

Medical Policy. MP Drug Testing in Pain Management and Substance Use Disorder Treatment

Medical Policy. MP Drug Testing in Pain Management and Substance Use Disorder Treatment Medical Policy BCBSA Ref. Policy: 2.04.98 Last Review: 12/20/2018 Effective Date: 12/20/2018 Section: Medicine Related Policies 2.01.30 Biofeedback as a Treatment of Chronic Pain 5.01.16 Intravenous Anesthetics

More information

Screening Pregnant and Postpartum Women for Substance Use Disorder. MPQC Fall Summit November 14, 2018

Screening Pregnant and Postpartum Women for Substance Use Disorder. MPQC Fall Summit November 14, 2018 Screening Pregnant and Postpartum Women for Substance Use Disorder MPQC Fall Summit November 14, 2018 Disclosures No relevant financial or non-financial relafonships Screening Pregnant and Postpartum Women

More information

You Can t Fool the Bladder Police. Effective Use of Urine Drug Screening

You Can t Fool the Bladder Police. Effective Use of Urine Drug Screening You Can t Fool the Bladder Police Effective Use of Urine Drug Screening Why Test? Accountability Create and maintain safe treatment environment Compliance with licensing or policy Collection Supervised

More information

A Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen

A Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen Section Editor: Kelly M. Smith, PharmD, BCPS, FASHP, FCCP A Review of the Methods, Interpretation, and Limitations of the Urine Drug Screen E. Claire Markway, PharmD; Stephanie N. Baker, PharmD, BCPS Abstract:

More information

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories

More information

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Payment Policy: Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing EDUCATIONAL COMMENTARY 2003 3 rd TEST EVENT Chemistry Urine Drug Testing Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE

More information

Recognizing Narcotic Abuse and Addiction and Helping Those With It

Recognizing Narcotic Abuse and Addiction and Helping Those With It Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved

More information

EDUCATIONAL COMMENTARY METHADONE

EDUCATIONAL COMMENTARY METHADONE EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education

More information

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program North Sydney April 12, 2018 This speaker has been asked to disclose to the audience any involvement with

More information

nextgen precision Test Report

nextgen precision Test Report nextgen precision TM Test Report SUMMARY OF PRECISION S NEXTGEN TEST REPORT In an effort to provide as much clinical insight as possible to our providers, we created our comprehensive NextGen Precision

More information

Urine Drug Screening: A Valuable Office Procedure

Urine Drug Screening: A Valuable Office Procedure Page 1 of 12 American Family Physician Return to Previous Page Mar 1, 2010 Table of Contents Urine Drug Screening: A Valuable Office Procedure JOHN B. STANDRIDGE, MD; STEPHEN M. ADAMS, MD; and ALEXANDER

More information

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D. Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals

More information

Medical Affairs Policy

Medical Affairs Policy Medical Affairs Policy Service: Urine Drug/Alcohol Screening and Testing PUM 250-0013-1803 Medical Policy Committee Approval 03/06/18 Effective Date 07/01/18 Prior Authorization Needed No Disclaimer: This

More information

9/17/2014. Monitoring Controlled Substances. Objectives. Presription Painkiller Overdose

9/17/2014. Monitoring Controlled Substances. Objectives. Presription Painkiller Overdose Monitoring Controlled Substances Nicole Paterson, PharmD BCPS And Michelle Herr, PharmD MTM Pharmacists 9/12/2014 Objectives Describe why we care about controlled substances Provide a few guidelines on

More information

Chronic Pain Pharmacist role in the clinic

Chronic Pain Pharmacist role in the clinic Chronic Pain Pharmacist role in the clinic WSPA Annual Meeting 2015 Alvin Goo, PharmD Clinical Associate Professor University of Washington Schools of Pharmacy and Family Medicine Speakers Declaration

More information

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital What Your Drug Test Really Means Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital Disclosure There are no relevant financial relationships with commercial interests associated.

More information

Pain Medication Management Program Supports Patient Outcomes and Adherence

Pain Medication Management Program Supports Patient Outcomes and Adherence PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety

More information

Drug Adherence Assessment Report

Drug Adherence Assessment Report Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)

More information

Appropriate Prescribing of Opioids for Chronic Non Cancer Pain

Appropriate Prescribing of Opioids for Chronic Non Cancer Pain Appropriate Prescribing of Opioids for Chronic Non Cancer Pain Dr. Cheri Olson La Crosse Mayo Family Medicine Residency Assistant Professor of Family Medicine, Mayo Graduate School of Medicine Disclosure

More information

Urine Drug Testing In Pain Management and Substance Abuse Treatment Corporate Medical Policy

Urine Drug Testing In Pain Management and Substance Abuse Treatment Corporate Medical Policy Urine Drug Testing In Pain Management and Substance Abuse Treatment Corporate Medical Policy File Name: Urine Drug Testing in Pain Management and Substance Abuse Treatment File Code: UM.SPSVC.09 Last Review:

More information

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer

More information

Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018

Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Opioid Prescribing Tips & Tricks CANDY STOCKTON, MD MAY 2018 Disclosures None Educational Objectives Understand CA state medical board guidelines for prescribing opioids for chronic pain Understand the

More information

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,

More information

Jennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of Toronto

Jennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of Toronto Team Based Approaches to Chronic Pain Management: Opioid Stewardship Jennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of

More information

Section I. Short-acting opioid Prior Authorization Criteria

Section I. Short-acting opioid Prior Authorization Criteria Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization

More information

Disclosures. Preventing, Recognizing and Managing Opiate Use Disorders. Opioids in the US 10/13/17

Disclosures. Preventing, Recognizing and Managing Opiate Use Disorders. Opioids in the US 10/13/17 Disclosures Preventing, Recognizing and Managing Opiate Use Disorders n None Katherine Julian, M.D. Professor of Medicine UCSF Division of General Internal Medicine October 13, 2017 Opioids in the US n

More information

Treatment Agreements Clinical Contracts. Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017

Treatment Agreements Clinical Contracts. Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017 Treatment Agreements Clinical Contracts Dr. Paul A. Farnan, Dr. Johan Wouterloot Prescribers Course, Vancouver, BC, Canada October 13, 2017 Faculty/presenter disclosure Presenter: Dr. Paul Farnan Relationships

More information

Beating Drug Tests and Defending Positive Results

Beating Drug Tests and Defending Positive Results Beating Drug Tests and Defending Positive Results Amitava Dasgupta Beating Drug Tests and Defending Positive Results A Toxicologist s Perspective Amitava Dasgupta Department of Pathology and Laboratory

More information

Drug Screening: Things You Need to Know

Drug Screening: Things You Need to Know Drug Screening: Things You Need to Know (a view inside the clinical laboratory) Gary L. Horowitz, MD Director, Clinical Chemistry, Beth Israel Deaconess Medical Center Associate Professor of Pathology,

More information

Pain Medication Management Program Monitors Patient Compliance

Pain Medication Management Program Monitors Patient Compliance PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your

More information

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing POLICY: PG0069 ORIGINAL EFFECTIVE: 01/01/11 LAST REVIEW: 11/13/18 MEDICAL POLICY Drug Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each

More information

Practical Pain Assessment- Screening for Psychosocial Risk. Session #3 Roman D. Jovey, MD

Practical Pain Assessment- Screening for Psychosocial Risk. Session #3 Roman D. Jovey, MD Practical Pain Assessment- Screening for Psychosocial Risk Session #3 Roman D. Jovey, MD Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Striking a Balance: a provider perspective.

Striking a Balance: a provider perspective. Striking a Balance: a provider perspective kpfeifer@chcf.org Beth s story 38 years old, erratically employed Counseling doesn t help Chronic low back pain after car accident 8 Vicodin/day grew to 180 mg

More information

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. 1/25/17 PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. PISA Physicians Kenneth B. Gossler M.D. Education University of Arizona Med School 1992. THMEP Intern 1993 Anesthesiology Residency at Financial

More information

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082 Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

Prescribing drugs of dependence in general practice, Part C

Prescribing drugs of dependence in general practice, Part C HO O Prescribing drugs of dependence in general practice, Part C Key recommendations and practice points for management of pain with opioid therapy H H HO N CH3 Acute pain Acute pain is an unpleasant sensory

More information

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA Department of Veterans Affairs Network Policy No.: 2014-01 VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Bill McCarberg, MD. Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired)

Bill McCarberg, MD. Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired) Pain Management Bill McCarberg, MD Founder Chronic Pain Management Program Kaiser Permanente San Diego (retired) Adjunct Assistant Clinical Professor University of California School of Medicine San Diego

More information

Drug Testing: How to Evaluate Results

Drug Testing: How to Evaluate Results Drug Testing: How to Evaluate Results Prepared for you by the West Virginia Drug Testing Laboratory Drug testing, whether for an individual or a large corporation, consists of two necessary steps - specimen

More information

Can adderall cause a false positive on a drug test

Can adderall cause a false positive on a drug test Can adderall cause a false positive on a drug test The Borg System is 100 % Can adderall cause a false positive on a drug test If you're about to take a drug test, watch out if you are taking one of these

More information

Drug & Alcohol Testing in. Canada. Point of Care Testing

Drug & Alcohol Testing in. Canada. Point of Care Testing Drug & Alcohol Testing in Canada Point of Care Testing Introduction We are the leading Canadian innovator of diagnostic testing products and services Verify Diagnostics has assisted governments, corporations,

More information

Dr. Melissa Holowaty HAVELOCK ON 146 BUPRENORPHINE IN RURAL PRACTICE FOR OPIOID USE DISORDER

Dr. Melissa Holowaty HAVELOCK ON 146 BUPRENORPHINE IN RURAL PRACTICE FOR OPIOID USE DISORDER Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 Dr. Melissa Holowaty HAVELOCK ON 146 BUPRENORPHINE IN RURAL PRACTICE

More information

Many companies conduct drug screenings. But you better avoid the following nine items and save yourself a world of frustration, if you need

Many companies conduct drug screenings. But you better avoid the following nine items and save yourself a world of frustration, if you need 18-8-2017 Many companies conduct drug screenings. But you better avoid the following nine items and save yourself a world of frustration, if you need to pass the test 2-2-2018 25 Answers (question resolved)

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date

More information

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids? Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities

More information

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-47 Effective Date: 07/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions

More information

Guidelines for Urine Drug Monitoring for the Pain Patient in a Clinical Practice

Guidelines for Urine Drug Monitoring for the Pain Patient in a Clinical Practice Guidelines for Urine Drug Monitoring for the Pain Patient in a Clinical Practice Howard A. Heit, M.D., F.A.C.P., F.A.S.A.M. Board Certified in Internal Medicine and Gastroenterology/Hepatology Certified

More information

PROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015

PROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015 Matthew H. Mead Governor State of Wyoming Department of Workforce Services DIVISION OF WORKERS COMPENSATION 1510 East Pershing Boulevard, South Wing Cheyenne, Wyoming 82002 http://www.wyomingworkforce.org

More information

Subject: Pain Management (Page 1 of 7)

Subject: Pain Management (Page 1 of 7) Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all

More information